Samjin Pharmaceuticals Co., Ltd. (005500.KS)
KRW 18280.0
(-0.33%)
KRW 18280.0
(-0.33%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 154.53 Billion KRW | 18.24% |
| 2022 | 130.69 Billion KRW | 32.92% |
| 2021 | 98.32 Billion KRW | 76.92% |
| 2020 | 55.57 Billion KRW | 19.07% |
| 2019 | 46.67 Billion KRW | 3.84% |
| 2018 | 44.95 Billion KRW | -7.09% |
| 2017 | 48.38 Billion KRW | -16.41% |
| 2016 | 57.87 Billion KRW | -20.36% |
| 2015 | 72.67 Billion KRW | -12.72% |
| 2014 | 83.26 Billion KRW | -8.46% |
| 2013 | 90.96 Billion KRW | -0.53% |
| 2012 | 91.44 Billion KRW | 3.65% |
| 2011 | 88.22 Billion KRW | 23.26% |
| 2010 | 71.57 Billion KRW | -8.28% |
| 2009 | 78.03 Billion KRW | 3.12% |
| 2008 | 75.67 Billion KRW | 25.46% |
| 2007 | 60.31 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 160.72 Billion KRW | 4.01% |
| 2024 Q2 | 158.82 Billion KRW | -1.18% |
| 2023 Q4 | 154.53 Billion KRW | -1.21% |
| 2023 Q1 | 149.45 Billion KRW | 15.25% |
| 2023 Q2 | 155.37 Billion KRW | 3.96% |
| 2023 FY | 154.53 Billion KRW | 18.24% |
| 2023 Q3 | 156.42 Billion KRW | 0.68% |
| 2022 Q4 | 129.67 Billion KRW | -0.5% |
| 2022 Q2 | 122.57 Billion KRW | -3.77% |
| 2022 Q1 | 127.37 Billion KRW | 29.54% |
| 2022 FY | 130.69 Billion KRW | 32.92% |
| 2022 Q3 | 130.31 Billion KRW | 6.32% |
| 2021 Q3 | 90.9 Billion KRW | 23.27% |
| 2021 Q2 | 73.74 Billion KRW | -0.52% |
| 2021 FY | 98.32 Billion KRW | 76.92% |
| 2021 Q1 | 74.12 Billion KRW | 33.38% |
| 2021 Q4 | 98.32 Billion KRW | 8.17% |
| 2020 FY | 55.57 Billion KRW | 19.07% |
| 2020 Q3 | 59.43 Billion KRW | 3.59% |
| 2020 Q4 | 55.57 Billion KRW | -6.49% |
| 2020 Q1 | 60.55 Billion KRW | 29.74% |
| 2020 Q2 | 57.37 Billion KRW | -5.26% |
| 2019 Q4 | 46.67 Billion KRW | 37.97% |
| 2019 Q3 | 33.83 Billion KRW | -21.79% |
| 2019 FY | 46.67 Billion KRW | 3.84% |
| 2019 Q1 | 55.74 Billion KRW | 24.0% |
| 2019 Q2 | 43.25 Billion KRW | -22.4% |
| 2018 Q1 | 59.69 Billion KRW | 23.38% |
| 2018 Q3 | 47.31 Billion KRW | 4.48% |
| 2018 Q2 | 45.28 Billion KRW | -24.13% |
| 2018 Q4 | 44.95 Billion KRW | -5.0% |
| 2018 FY | 44.95 Billion KRW | -7.09% |
| 2017 Q3 | 51.64 Billion KRW | 5.82% |
| 2017 Q2 | 48.8 Billion KRW | -23.63% |
| 2017 Q1 | 63.9 Billion KRW | 10.42% |
| 2017 FY | 48.38 Billion KRW | -16.41% |
| 2017 Q4 | 48.38 Billion KRW | -6.33% |
| 2016 Q1 | 71.06 Billion KRW | -2.21% |
| 2016 Q3 | 53.69 Billion KRW | -8.07% |
| 2016 Q2 | 58.4 Billion KRW | -17.81% |
| 2016 Q4 | 57.87 Billion KRW | 7.8% |
| 2016 FY | 57.87 Billion KRW | -20.36% |
| 2015 FY | 72.67 Billion KRW | -12.72% |
| 2015 Q4 | 72.67 Billion KRW | -10.3% |
| 2015 Q3 | 81.01 Billion KRW | -1.86% |
| 2015 Q2 | 82.55 Billion KRW | -7.69% |
| 2015 Q1 | 89.42 Billion KRW | 7.4% |
| 2014 Q2 | 86.73 Billion KRW | -5.03% |
| 2014 Q3 | 82.45 Billion KRW | -4.93% |
| 2014 FY | 83.26 Billion KRW | -8.46% |
| 2014 Q4 | 83.26 Billion KRW | 0.98% |
| 2014 Q1 | 91.32 Billion KRW | 0.4% |
| 2013 Q3 | 100.61 Billion KRW | -4.48% |
| 2013 Q4 | 90.96 Billion KRW | -9.59% |
| 2013 FY | 90.96 Billion KRW | -0.53% |
| 2013 Q1 | 93.12 Billion KRW | 1.84% |
| 2013 Q2 | 105.32 Billion KRW | 13.1% |
| 2012 Q2 | 75.23 Billion KRW | -11.35% |
| 2012 Q1 | 84.87 Billion KRW | -3.8% |
| 2012 FY | 91.44 Billion KRW | 3.65% |
| 2012 Q4 | 91.44 Billion KRW | 25.13% |
| 2012 Q3 | 73.08 Billion KRW | -2.87% |
| 2011 Q3 | 93.36 Billion KRW | 1.63% |
| 2011 Q4 | 88.22 Billion KRW | -5.51% |
| 2011 FY | 88.22 Billion KRW | 23.26% |
| 2011 Q1 | 88.48 Billion KRW | 23.63% |
| 2011 Q2 | 91.86 Billion KRW | 3.82% |
| 2010 Q4 | 71.57 Billion KRW | -8.53% |
| 2010 Q3 | 78.24 Billion KRW | -2.82% |
| 2010 FY | 71.57 Billion KRW | -8.28% |
| 2010 Q1 | 82.69 Billion KRW | 5.97% |
| 2010 Q2 | 80.51 Billion KRW | -2.63% |
| 2009 Q2 | 80.93 Billion KRW | 0.77% |
| 2009 FY | 78.03 Billion KRW | 3.12% |
| 2009 Q4 | 78.03 Billion KRW | -5.02% |
| 2009 Q3 | 82.15 Billion KRW | 1.5% |
| 2009 Q1 | 80.31 Billion KRW | 6.14% |
| 2008 Q4 | 75.67 Billion KRW | -0.13% |
| 2008 Q2 | 68.8 Billion KRW | -4.79% |
| 2008 Q1 | 72.27 Billion KRW | 19.82% |
| 2008 Q3 | 75.77 Billion KRW | 10.12% |
| 2008 FY | 75.67 Billion KRW | 25.46% |
| 2007 Q1 | 59.89 Billion KRW | 0.0% |
| 2007 FY | 60.31 Billion KRW | 0.0% |
| 2007 Q4 | 60.31 Billion KRW | -9.83% |
| 2007 Q3 | 66.89 Billion KRW | 11.03% |
| 2007 Q2 | 60.24 Billion KRW | 0.59% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -98.485% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 83.38% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 78.145% |
| HANDOK Inc. | 449.7 Billion KRW | 65.636% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -80.385% |
| Yuhan Corporation | 712.33 Billion KRW | 78.306% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 75.545% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -872.263% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 81.858% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -188.698% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 24.937% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -105.58% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -4.562% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -119.508% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -98.485% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -324.128% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 38.469% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 29.981% |
| JW Holdings Corporation | 827.51 Billion KRW | 81.325% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 64.637% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 73.664% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 59.29% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -94.872% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -120.868% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 36.366% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 53.213% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -98.485% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 68.463% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 81.989% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 59.29% |
| Yuhan Corporation | 712.33 Billion KRW | 78.306% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 67.657% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -12.826% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 70.09% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 59.29% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -71.773% |
| CKD Bio Corp. | 170.76 Billion KRW | 9.501% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 36.596% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | 1.979% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -259.227% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -94.872% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 75.568% |
| Boryung Corporation | 373.1 Billion KRW | 58.581% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 25.774% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 24.937% |
| JW Lifescience Corporation | 96.44 Billion KRW | -60.235% |